JP2007532685A5 - - Google Patents

Download PDF

Info

Publication number
JP2007532685A5
JP2007532685A5 JP2007508646A JP2007508646A JP2007532685A5 JP 2007532685 A5 JP2007532685 A5 JP 2007532685A5 JP 2007508646 A JP2007508646 A JP 2007508646A JP 2007508646 A JP2007508646 A JP 2007508646A JP 2007532685 A5 JP2007532685 A5 JP 2007532685A5
Authority
JP
Japan
Prior art keywords
composition
pathological condition
antagonist
egfl7
angiogenic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007508646A
Other languages
English (en)
Japanese (ja)
Other versions
JP5599136B2 (ja
JP2007532685A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/013658 external-priority patent/WO2005117968A2/en
Publication of JP2007532685A publication Critical patent/JP2007532685A/ja
Publication of JP2007532685A5 publication Critical patent/JP2007532685A5/ja
Application granted granted Critical
Publication of JP5599136B2 publication Critical patent/JP5599136B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007508646A 2004-04-14 2005-04-14 血管の発達を調節するための、egfl7アンタゴニストを含む組成物 Expired - Fee Related JP5599136B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56205404P 2004-04-14 2004-04-14
US60/562,054 2004-04-14
PCT/US2005/013658 WO2005117968A2 (en) 2004-04-14 2005-04-14 Compositions and methods comprising an egfl7 antagonist for modulating vascular development

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011190733A Division JP2011241230A (ja) 2004-04-14 2011-09-01 血管の発達を調節するための、egfl7アンタゴニストを含む組成物および方法

Publications (3)

Publication Number Publication Date
JP2007532685A JP2007532685A (ja) 2007-11-15
JP2007532685A5 true JP2007532685A5 (https=) 2008-05-29
JP5599136B2 JP5599136B2 (ja) 2014-10-01

Family

ID=35355481

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2007508646A Expired - Fee Related JP5599136B2 (ja) 2004-04-14 2005-04-14 血管の発達を調節するための、egfl7アンタゴニストを含む組成物
JP2011190733A Withdrawn JP2011241230A (ja) 2004-04-14 2011-09-01 血管の発達を調節するための、egfl7アンタゴニストを含む組成物および方法
JP2013196507A Withdrawn JP2013256535A (ja) 2004-04-14 2013-09-24 血管の発達を調節するための、egfl7アンタゴニストを含む組成物および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2011190733A Withdrawn JP2011241230A (ja) 2004-04-14 2011-09-01 血管の発達を調節するための、egfl7アンタゴニストを含む組成物および方法
JP2013196507A Withdrawn JP2013256535A (ja) 2004-04-14 2013-09-24 血管の発達を調節するための、egfl7アンタゴニストを含む組成物および方法

Country Status (14)

Country Link
US (3) US20070031437A1 (https=)
EP (1) EP1734998A2 (https=)
JP (3) JP5599136B2 (https=)
KR (1) KR101227817B1 (https=)
CN (2) CN1997394B (https=)
AU (1) AU2005249377A1 (https=)
BR (1) BRPI0509420A (https=)
CA (1) CA2563445C (https=)
IL (2) IL178329A0 (https=)
MX (1) MXPA06011851A (https=)
NZ (1) NZ550110A (https=)
RU (3) RU2365382C2 (https=)
WO (1) WO2005117968A2 (https=)
ZA (1) ZA200608615B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06011851A (es) * 2004-04-14 2006-12-14 Genentech Inc Composiciones y metodos para moduilar el desarrollo vascular.
AR059851A1 (es) * 2006-03-16 2008-04-30 Genentech Inc Anticuerpos de la egfl7 y metodos de uso
US8541559B2 (en) 2006-06-12 2013-09-24 Cytos Biotechnology Ag Process for producing aggregated oligonucleotides
WO2008010986A2 (en) * 2006-07-17 2008-01-24 The Board Of Trustees Of The Leland Stanford Junior University Methods of modulating angiogenesis
WO2008130719A1 (en) * 2007-04-24 2008-10-30 University Of Louisville Therapeutic beta-glucan combinations
JP2009005584A (ja) * 2007-06-26 2009-01-15 Miyazaki Prefecture ゲル化剤、凍結保存剤、細胞保存用容器、細胞の凍結保存方法、細胞の融解方法、哺乳動物の細胞
EP2235189A1 (en) * 2008-01-14 2010-10-06 Genentech, Inc. Methods for inhibiting angiogenesis using egfl8 antagonists
WO2010034155A1 (zh) * 2008-09-25 2010-04-01 中南大学湘雅医院 一种通过检测样品中eglf7来诊断肝细胞癌的试剂盒
PE20120902A1 (es) * 2009-05-08 2012-08-08 Genentech Inc Anticuerpos anti-egfl7 humanizados
RU2412251C1 (ru) * 2009-06-15 2011-02-20 Юрий Леонидович Дорохов Антитело против фактора роста эндотелия сосудов и способ продукции антитела в растении
AU2010273585B2 (en) * 2009-07-13 2015-04-23 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
BR112012013093A2 (pt) * 2009-12-21 2017-12-12 Genentech Inc ''formulação farmacêutica aquosa estável, artigo, métodos para estabilizar um anticorpo, para tratamento de uma doença ou distúrbio em um indivíduo, para reduzir a agregação de um anticorpo monoclonal terapêutico e de fabricação de uma formulação farmaceutica, frasco e tanque de aço inoxidável
WO2013061112A1 (en) 2011-10-24 2013-05-02 Centre National De La Recherche Scientifique Use of egfl7 modulators for promoting or inhibiting migration of immune cells across vascular endothelium
EP2831093A4 (en) * 2012-03-27 2015-11-04 London Health Sci Ct Res Inc EGFL7-targeting or binding polypeptides and methods for inhibiting angiogenesis
US20170007495A1 (en) * 2013-11-21 2017-01-12 Mfr Products, Inc. Therapeutic device to assist in myofascial release, and method of use
RU2729161C2 (ru) * 2014-10-23 2020-08-04 ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. Фармацевтические композиции, содержащие варианты пептидов, и способы их применения
CN105543183B (zh) * 2016-01-08 2019-04-12 吴帆 人肝癌细胞Egfl8基因过表达慢病毒在制备治疗肝癌药物中的应用
US11702469B2 (en) 2017-04-24 2023-07-18 Ohio State Innovation Foundation Recombinant EGFL7, EGFL7 antibodies, and uses thereof
RU2678200C1 (ru) * 2018-07-27 2019-01-24 Федеральное государственное бюджетное научное учреждение "Иркутский научный центр хирургии и травматологии" Лекарственная пленка пролонгированного действия и способ её получения
DE212020000830U1 (de) 2020-07-28 2023-10-30 Limited Liability Company "Angiolife" Verwendung einer Kombination von Genen angiogener und neurotropher Faktoren
CN114410642B (zh) * 2021-12-31 2023-01-17 苏州大学 一种急性t淋巴细胞白血病药物靶点及其应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0248088A4 (en) * 1985-11-22 1988-05-03 Teijin Ltd VASCULARIZATION FACTOR AND MANUFACTURING.
EP0318488A4 (en) 1986-08-18 1990-02-26 Biota Scient Management STIMULATION OF ANGIOGENESIS AND PROMOTION OF ENDOTHELIALIZATION.
SK163598A3 (en) * 1996-05-31 1999-06-11 Scripps Research Inst Methods and compositions useful for inhibition of angiogenesis
WO2002000690A2 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO2002008284A2 (en) 2000-07-20 2002-01-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US20020137890A1 (en) 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000053752A2 (en) 1999-03-08 2000-09-14 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
AU737132B2 (en) * 1997-06-18 2001-08-09 Zymogenetics Inc. Mammalian neuro-growth factor like protein
US20030166907A1 (en) * 1997-06-18 2003-09-04 Zymogenetics, Inc. Mammalian neuro-growth factor like protein
US5972338A (en) 1997-09-19 1999-10-26 Genentech, Inc. Tie ligands homologues
US20030022293A1 (en) 1997-09-18 2003-01-30 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6974696B2 (en) 1997-10-17 2005-12-13 Genentech, Inc. PRO853 nucleic acids
US6391311B1 (en) 1998-03-17 2002-05-21 Genentech, Inc. Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1
US20030069178A1 (en) 1997-10-17 2003-04-10 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7105640B2 (en) 1997-10-17 2006-09-12 Genentech, Inc. Anti-pro792 antibodies
US7196165B2 (en) 1997-10-17 2007-03-27 Genentech, Inc. PRO363 polypeptides
US20030039648A1 (en) 1998-09-16 2003-02-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
US7419663B2 (en) 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
ES2312205T3 (es) 1998-03-10 2009-02-16 Genentech, Inc. Nuevo polipeptido y acidos nucleicos que lo codifican.
US7371836B2 (en) 1998-03-27 2008-05-13 Genentech, Inc. PRO526 nucleic acids
US7202338B2 (en) 1998-03-31 2007-04-10 Genentech, Inc. PRO731 polypeptides
US7166700B2 (en) 1998-04-01 2007-01-23 Genentech, Inc. PRO703 Polypeptides
US6962797B2 (en) 1998-04-15 2005-11-08 Genentech, Inc. Nucleic acids encoding PRO615
DE19817946A1 (de) 1998-04-17 1999-10-21 Metagen Gesellschaft Fuer Genomforschung Mbh Menschliche Nukleinsäuresequenzen aus Uterus-Normalgewebe
AU3965799A (en) 1998-04-23 1999-11-08 Millennium Pharmaceuticals, Inc. Novel molecules of the t125-related protein family and uses thereof
US7067636B2 (en) 1998-05-06 2006-06-27 Genentech, Inc. Anti-pro 1017 antibodies
US7279553B2 (en) 1998-05-13 2007-10-09 Genentech, Inc. PRO1083 polypeptides
US7771719B1 (en) 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
US7019115B2 (en) 1998-05-22 2006-03-28 Genentech, Inc. Pro1017 polypeptides
US7220835B2 (en) 1998-07-30 2007-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2001054477A2 (en) 2000-01-25 2001-08-02 Hyseq, Inc. Novel nucleic acids and polypeptides
CA2353797A1 (en) 1998-12-11 2000-06-15 Incyte Pharmaceuticals, Inc. Neuron-associated proteins
US20030009013A1 (en) 1998-12-30 2003-01-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000058473A2 (en) 1999-03-31 2000-10-05 Curagen Corporation Nucleic acids including open reading frames encoding polypeptides; 'orfx'
WO2000063756A1 (en) 1999-04-16 2000-10-26 Fujikin Incorporated Parallel bypass type fluid feeding device, and method and device for controlling fluid variable type pressure system flow rate used for the device
US7214656B2 (en) 1999-04-28 2007-05-08 Genentech, Inc. PRO792 polypeptides
JP2003504021A (ja) 1999-07-02 2003-02-04 財団法人相模中央化学研究所 疎水性ドメインを有するヒトプロテイン並びにそれをコードするdna
US7589172B2 (en) 1999-07-20 2009-09-15 Genentech, Inc. PRO256 polypeptides
TWI265167B (en) 1999-11-29 2006-11-01 Akzo Nobel Nv 3-methylene steroid derivatives
US7193050B2 (en) 2000-02-18 2007-03-20 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7442765B2 (en) 2000-08-24 2008-10-28 Genentech, Inc. Secreted transmembrane polypeptides and nucleic acids encoding the same
US7265210B2 (en) 2000-09-15 2007-09-04 Genentech, Inc. Anti-PRO9821 antibodies
WO2002076486A2 (en) * 2001-02-05 2002-10-03 Innoventus Project Ab Histidine-rich glycoprotein
US20030224984A1 (en) * 2001-06-20 2003-12-04 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US7164007B2 (en) 2001-06-20 2007-01-16 Genentech, Inc. Anti-PR020044 antibodies
FR2851249A1 (fr) * 2003-02-17 2004-08-20 Commissariat Energie Atomique Nouveau facteur soluble secrete par les cellules endotheliales des vaisseaux sanguins, capable d'inhiber le recrutement des cellules perivasculaires du type musculaire lisse et ses applications
MXPA06011851A (es) 2004-04-14 2006-12-14 Genentech Inc Composiciones y metodos para moduilar el desarrollo vascular.

Similar Documents

Publication Publication Date Title
JP2007532685A5 (https=)
RU2006140081A (ru) Композиции и способы для регуляции развития сосудов
JP2007262090A5 (https=)
JP2014508753A5 (https=)
JP2010285439A5 (https=)
JP2008513467A5 (https=)
ATE516285T1 (de) Dihydropyridinonderivate
JP2009503105A5 (https=)
JP2021509912A5 (https=)
JP2014012726A5 (https=)
JP2010120964A5 (https=)
JP2007526455A5 (https=)
JP2016539089A5 (https=)
JP2019520550A5 (https=)
JP2010222367A5 (https=)
JP2007520566A5 (https=)
JP2014512396A5 (https=)
JP2011522816A5 (https=)
JP2008527066A5 (https=)
JP2012255007A5 (https=)
JP2009538898A5 (https=)
JP2010520200A5 (https=)
JP2007535560A5 (ja) A1アデノシンレセプターアンタゴニストとしてのプリン誘導体
EP2208498A4 (en) PHARMACEUTICAL COMPOSITION OF A COMBINATION OF VARIOUS VENOTONIC AND VASO-PROTECTIVE AGENTS FOR THE TREATMENT OF CHRONIC VEININ INSUFFICIENCY
JP2015526455A5 (https=)